HER2-Directed Therapy, Trastuzumab Deruxtecan, Approved for Metastatic NSCLC
August 12th 2022The FDA has approved trastuzumab deruxtecan for patients with HER2-mutated non–small cell lung cancer after the DESTINY-Lung02 results demonstrated a 57% overall response rate with the agent. The drug comes with warning for interstitial lung disease, neutropenia, and left ventricular dysfunction.